Related Experiment Videos
Polyglutamine disease: acetyltransferases awry.
1Division of Medical Genetics, Box 357720, University of Washington, Seattle, Washington 98195, USA. rehughes.u.washington.edu
Current Biology : CB
|February 28, 2002
Summary
Inhibition of histone acetyltransferases may cause cellular damage in Huntington disease. Modifying protein acetylation could offer a potential therapeutic strategy for these neurodegenerative conditions.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Polyglutamine diseases, such as Huntington disease, are linked to cellular pathogenesis.
- Histone acetyltransferases (HATs) play a crucial role in regulating gene expression and cellular function.
Purpose of the Study:
- To investigate the role of histone acetyltransferase inhibition in the pathogenesis of polyglutamine diseases.
- To explore the therapeutic potential of modulating protein acetylation levels.
Main Methods:
- The study examined the effects of inhibiting histone acetyltransferases in cellular models relevant to polyglutamine diseases.
- Analysis focused on cellular pathogenesis and protein acetylation markers.
Main Results:
- Evidence suggests that inhibition of histone acetyltransferases is a key factor in the cellular pathology of polyglutamine diseases.
- These findings highlight the link between protein acetylation and disease mechanisms.
Conclusions:
- Inhibition of histone acetyltransferases contributes to cellular pathogenesis in polyglutamine diseases like Huntington disease.
- Pharmacologic manipulation of protein acetylation presents a promising therapeutic avenue for these disorders.